Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vir Biotechnology Inc. Common Stock (VIR) vs Vertiv Holdings Co (VRT) Price & Performance

Vir Biotechnology Inc. Common StockTrade
Vertiv Holdings CoTrade

Price performance (Past 24H)

Key statistics

Vir Biotechnology Inc. Common Stock vs Vertiv Holdings Co — how do they compare? Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B), while Vertiv Holdings Co trades at $217.98 (market cap $91.35B). The key difference: Vertiv Holdings Co is far larger — about 50.8× Vir Biotechnology Inc. Common Stock's market cap, and Vertiv Holdings Co pays a 0.11% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vir Biotechnology Inc. Common Stock for 0 Days and Vertiv Holdings Co for 40 Days on average.

VIRVRT
Market Cap
$1.80B$91.35B
Volume
1,782,8364,805,860
Sector
HealthIndustrials
52-Week High
$11.78$376.23
52-Week Low
$5.12$149.83
Typical Hold Time
0 Days40 Days
Enterprise Value
$1.36B$91.58B
Dividend Yield
—0.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Vertiv Holdings Co

Vertiv (VRT) trades at $237.29, down 0.86% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with revenue growth from $10.23B in 2025 to $11.5B projected for 2026 and a robust net income margin of 15.09%. Recent earnings have consistently beaten estimates, and analyst sentiment remains overwhelmingly positive with a 90.48% buy rating and a consensus price target of $366.12. However, technical indicators show selling pressure, with the price near support at $237.

The outlook for VRT is favorable due to its strategic position in the AI data center infrastructure market, driving revenue and margin expansion. Key risks include execution of growth initiatives, competitive pressures, and market volatility. The significant upside to the analyst target presents a potential opportunity, but investors should weigh the strong fundamentals against the current technical weakness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VIR
51% Buy49% Sell
Avg holding period · 0 Days
VRT
32% Buy68% Sell
Avg holding period · 40 Days

Top news

Latest headlines on both assets

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →

About Vertiv Holdings Co

Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.

Read more on VRT →